Ancestral differences in the impact genetic variants have on glycated hemoglobin can substantially affect the performance of HbA1c as a diagnostic test for type 2 diabetes, results of a large trans-ethnic genome-wide meta-analysis show.

The PURE study shows that the cardiovascular disease and mortality risk reductions attainable with regular physical activity apply regardless of whether people live in countries with high, middle, or low income.

An EASD session on optimizing patient outcomes included research into the effect of guideline adherence, predictors of changes in medication adherence, and overtreatment of older people with diabetes.

Results of a pooled analysis suggest that the 300 U/mL dose of insulin glargine is associated with a lower risk for hypoglycemia than the 100 U/mL dose.

Adherence to lipid-lowering drugs is crucial for reducing cardiovascular disease risk among patients with type 2 diabetes, but taking only some of the prescribed medication is better than none at all, study results suggest.

Study results presented at the EASD annual meeting in Lisbon, Portugal, demonstrated the potential of several novel therapies for the treatment of obesity-related metabolic dysfunction and type 2 diabetes.